In 2023, the BREEZE-AD PEDS clinical trials highlighted the potential of baricitinib, a JAK1/JAK2 inhibitor, in pediatric patients with moderate to severe AD, who showed inadequate responses to TCSs [61]. This evidence concerns the gene JAK1 and Alzheimer disease.